Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anheuser-Busch InBev

Federal Realty Investment Trust

Leggett & Platt

Altria

Northwest Natural Gas

Investors Can Generate Huge Passive Income With 7 Dividend Kings

A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated dermatologic conditions and aesthetic indications NORTH CHICAGO, Ill. , March 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking presentations, during the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California.

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Enterprise Products Partners

Genuine Parts

Johnson & Johnson

Coca-Cola

Morgan Stanley

Procter & Gamble

Investors can effectively unlock financial freedom with dividend stocks to buy for a passive income stream. The key to invest in dividend stocks, promising a consistent and growing payout while offering steady capital gains.

The Top 7 Dividend Stocks to Buy in March 2024

AbbVie Inc. (NYSE:ABBV ) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 9:10 AM ET Company Participants Rob Michael - President, Chief Operating Officer and Incoming CEO Jeff Stewart - Executive Vice President and Chief Commercial Officer Roopal Thakkar - Senior Vice President Chief Medical Officer, Global Therapeutics Scott Reents - Executive Vice President and Chief Financial Officer Conference Call Participants Steve Scala - TD Cowen Steve Scala Okay. So, thank you and good morning.

AbbVie Inc. (ABBV) TD Cowen 44th Annual Health Care Conference (Transcript)

THE FIRST AND ONLY HYALURONIC ACID DERMAL FILLER APPROVED FOR THE IMPROVEMENT OF MODERATE TO SEVERE TEMPLE HOLLOWING1 IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET ®  to enter into clinical trials. WALTHAM, Mass.

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

Emerson Electric

Lowe's

Investing in dividend kings is about keeping things simple. A distinguishing feature of these companies is a rock-solid balance sheet that allows them to demonstrate unwavering commitment to building shareholder value.

Secure Your Future: 7 Dividend Kings with Solid Growth Potential

In the most recent trading session, AbbVie (ABBV) closed at $178.91, indicating a +1.62% shift from the previous trading day.

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

Amcor Plc

Franklin Resources

Realty Income Corp

T. Rowe Price Group

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE Ever wanted an extra set of eyes on an investment you're considering?

Buy These 7 Dividend Aristocrats for Huge 2024 Passive Income

Caterpillar

Walmart

It's often said that patience is a virtue for investors that often means taking advantage of the stability of blue-chip stocks.   However, that virtue can be sorely lacking among investors.

Blue-Chip Backbone: 3 Stocks for Unwavering Market Strength

Amgen

Dividend growth stocks have consistently outshined most other asset classes over the past 124 years. AbbVie and Amgen are two of the brightest stars within the healthcare dividend growth stock landscape.

Better Dividend Growth Stock: AbbVie or Amgen?

AbbVie's most important product is losing steam due to competition. The drugmaker is also facing a major leadership change right now.

Is AbbVie Stock a Buy Now?

NANTES, France--(BUSINESS WIRE)--OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership.

OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership

NORTH CHICAGO, Ill. & NANTES, France--(BUSINESS WIRE)--AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation.

AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation

PepsiCo

Pioneer Natural Resources

It operates through four segments: Upstream Energy Products Chemical Products Specialty Products  The Upstream segment explores and produces crude oil and natural gas.

5 Dividend Aristocrat Stocks Quietly Offering Huge Total Return Potential

NORTH CHICAGO, Ill. , Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024.

AbbVie to Present at the TD Cowen 44th Annual Health Care Conference

Genmab - ADR

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The FDA grants Priority Review to invest.

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

-   A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma (FL), demonstrating strong and durable treatment responses -   In November 2023, the FDA granted this investigational indication a Breakthrough Therapy Designation (BTD) NORTH CHICAGO, Ill. , Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody for the treatment of adult relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy.

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

Abbott Labs

UnitedHealth Group

UnitedHealth Group's dividend yield isn't huge, but it's raising the payout rapidly. AbbVie's dividend is in a slump, but it offers an above-average yield now and could start soaring in a couple of years.

3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade

Gilead Sciences

Eli Lilly

AbbVie is a Dividend King that's poised to soon return to robust growth. Eli Lilly's dividend is growing rapidly but is overshadowed by its tremendous stock gains.

3 Dividend Stocks That Are No-Brainer Buys Right Now

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix NORTH CHICAGO, Ill. and SAN DIEGO , Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.

AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY IRVINE, Calif. , Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

AbbVie Inc.'s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company's current president and chief operating officer, Robert Michael.

News for AbbVie Stock (ABBV)